FDA Approvals, AI Drug Discovery
Kilder
- Endpoints: FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data
- Endpoints: Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
- Endpoints: Iambic signs AbbVie deal, releases next generation of Enchant model
- Pharmexec: Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM - Pharmaceutical Executive
- Ca: AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery - Yahoo! Finance Canada
- Endpoints: ADARx targets $319M IPO as TRexBio, Retension join filing queue
- Raps: Recon: FDA staff raise no major concerns for Grail multi-cancer test ahead of adcomm; Trump admin drafting order to exert control over NIH grant funding - RAPS
- BioPharma Dive: How J&J paved the way for Compass’ coming psychedelic drug launch
- GEN: Advancing Cell Therapy for Cardiovascular Disease
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.